Drug Monograph

Drug Name: **Tecartus® (brexucabtagene autoleucel) cassette and infusion bag**
Drug Class: **Oncology: Chimeric Antigen Receptor (CAR) T-cell Gene Therapy**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Tecartus is now available in a 1 x 10^8 infusion bag and cassette.
Manufacturer:	Manufactured by: Kite Pharma, Inc., Santa Monica, CA 90404.
Indications:	Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: • Adult patients with relapsed or refractory mantle cell lymphoma (MCL) • Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Costs:	$399,000 per bag or cassette Wholesale Acquisition Cost
Summary of Findings:	The MO Healthnet Division recommends adding this drug to the current CAR T-cell Therapy clinical edit.
Status Recommendation:	☒ Clinical Edit ☐ PA Required ☐ Open Access ☐ PDL
Type of PA Criteria:	☒ Appropriate Indications ☐ Non-Preferred ☐ No PA Required ☐ Preferred

Prepared by: April Ash, PharmD
Date: December 30, 2021